{
  "id": 14052844,
  "title": "Efficacy of Tumor Treating Fields (TTFields) in triple negative breast cancer cells and synergy with PARP inhibitor talazoparib",
  "url": "https://urgent.news/2026/10/12/efficacy-of-tumor-treating-fields-ttfields-in-triple-negative-breast",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.10.09.757989v1?rss=1"
  },
  "original_language": "en",
  "account": "Breast cancer is the most prevalent form of cancer globally. Triple-negative breast cancer (TNBC) is a subtype that poses a significant challenge due to its aggressive nature and high propensity for recurrence. Researchers investigated the potential of Tumor Treating Fields (TTFields), a novel treatment modality, in conjunction with PARP inhibitors for TNBC management. TTFields employ alternating electric fields to impede cell growth and trigger cellular damage. The study revealed that TTFields elevate the expression of the cyclin-dependent kinase inhibitor protein p21(WAF1)/CDKN1A, irrespective of TP53 mutations. Furthermore, the combination of TTFields and the PARP inhibitor talazoparib led to an increased production of p21 protein. Both TTFields and talazoparib individually triggered cell death, as evidenced by PARP cleavage and the downregulation of cell growth markers and anti-apoptotic proteins, such as p-STAT3, STAT3, and MCL-1. Importantly, the concurrent use of talazoparib and TTFields resulted in DNA damage, as shown by heightened γH2AX expression. Additionally, the combination diminished PDL-1 levels, suggesting potential for future immune modulation strategies in cancer treatment. The preclinical findings propose TTFields alone or in combination with PARP inhibitors like talazoparib as a promising therapeutic avenue for further exploration in breast cancer treatment.",
  "summary": "Breast cancer is the most diagnosed cancer worldwide. Triple-negative breast cancer (TNBC) is a subtype with a poor prognosis because of its aggressiveness and high likelihood of relapse, making its treatment particularly challenging. We explored the effect of Tumor Treating Fields (TTFields) as a novel treatment option for breast cancer, which can be used together with other therapies, such as…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}